<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Drugs Ther</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Drugs Ther</journal-id><journal-title-group><journal-title>Cardiovascular Drugs and Therapy</journal-title></journal-title-group><issn pub-type="ppub">0920-3206</issn><issn pub-type="epub">1573-7241</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>Boston</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24842558</article-id><article-id pub-id-type="pmc">4074463</article-id><article-id pub-id-type="publisher-id">6523</article-id><article-id pub-id-type="doi">10.1007/s10557-014-6523-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kastelein</surname><given-names>John J. P.</given-names></name><address><phone>+31 20 566 6612</phone><email>j.j.kastelein@amc.uva.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>Jennifer G.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Farnier</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Krempf</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Langslet</surname><given-names>Gisle</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Lorenzato</surname><given-names>Christelle</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Gipe</surname><given-names>Daniel A.</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Baccara-Dinet</surname><given-names>Marie T.</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><aff id="Aff1"><label/>Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Room F4-159.2, 1105 AZ Amsterdam, The Netherlands </aff><aff id="Aff2"><label/>University of Iowa, Iowa City, IA USA </aff><aff id="Aff3"><label/>Point Medical, Dijon, France </aff><aff id="Aff4"><label/>CHU de Nantes - Hopital Nord Laennec, Saint-Herblain, France </aff><aff id="Aff5"><label/>Lipid Clinic, Oslo University Hospital, Oslo, Norway </aff><aff id="Aff6"><label/>Sanofi, Paris, France </aff><aff id="Aff7"><label/>Regeneron Pharmaceuticals, Inc., Tarrytown, NY USA </aff><aff id="Aff8"><label/>Sanofi, Montpellier, France </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>5</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>5</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>28</volume><issue>3</issue><fpage>281</fpage><lpage>289</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Individuals with heterozygous familial hypercholesterolemia (heFH) have higher levels of low-density lipoprotein cholesterol (LDL-C) and are predisposed to premature cardiovascular disease. Alirocumab is a fully-human, monoclonal antibody targeted to proprotein convertase subtilisin/kexin type 9 currently in Phase 3 development for the treatment of hypercholesterolemia. Described here are three ODYSSEY Phase 3 trials, FH I (NCT01623115), FH II (NCT01709500) and HIGH FH (patients with heFH and LDL-C levels &#x02265;160&#x000a0;mg/dL) (NCT01617655), in which alirocumab is further evaluated in the heFH population.</p></sec><sec><title>Methods</title><p>Multicenter, multinational, randomized, double-blind, placebo-controlled studies have been designed to evaluate efficacy and safety of alirocumab in more than 800 patients with heFH who are not adequately controlled with a maximally-tolerated stable daily dose of statin for &#x02265;4&#x000a0;weeks prior to the screening visit, with or without other lipid-lowering therapy. Patients are randomized (2:1) to receive alirocumab or placebo via a 1-mL subcutaneous auto-injection every 2&#x000a0;weeks (Q2W) for 78&#x000a0;weeks. In studies FH I and II, if their Week 8 LDL-C level is &#x02265;70&#x000a0;mg/dL, patients will undergo a dose uptitration from 75 to 150&#x000a0;mg alirocumab Q2W at Week 12. In HIGH FH, patients will receive alirocumab 150&#x000a0;mg Q2W throughout the entire treatment period. The primary efficacy endpoint in all three studies is the percent change in calculated LDL-C from baseline to Week 24.</p></sec><sec><title>Conclusions</title><p>The ODYSSEY FH studies are three Phase 3 studies aiming to further evaluate the efficacy and long-term safety of alirocumab as an effective therapeutic option for patients with heFH.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alirocumab</kwd><kwd>Heterozygous familial hypercholesterolemia</kwd><kwd>LDL-C</kwd><kwd>PCSK9</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media New York 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Heterozygous familial hypercholesterolemia (heFH) is a hereditary lipid metabolism disorder that predisposes affected individuals to cardiovascular (CV) disease [<xref ref-type="bibr" rid="CR1">1</xref>]. Patients with heFH typically have very high low-density lipoprotein cholesterol (LDL-C) levels&#x02014;often &#x0003e;190&#x000a0;mg/dL at the time of diagnosis&#x02014;that are associated with high risk for premature CV disease [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. However, a recent consensus statement highlights that in most countries less than 1&#x000a0;% of patients with heFH are, in fact, diagnosed [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>Findings from observational studies have shown that the risk of coronary heart disease (CHD) is reduced in heFH patients receiving statin therapy [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]; however, even with this treatment, the risk of CHD is still greater in heFH patients than in the general population [<xref ref-type="bibr" rid="CR5">5</xref>]. Despite the availability of lipid-lowering therapy (LLT), approximately 80&#x000a0;% of patients with heFH do not reach the recommended levels of LDL-C [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Given the increased CV risk in the heFH population, there is a need to provide patients with additional and more intensive lipid-lowering therapy [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p>Proprotein convertase subtilisin/kexin type 9 (PCSK9), a therapeutic target currently under investigation, binds to LDL-C receptors, resulting in their degradation so that fewer receptors are available on liver cells to remove excess LDL-C from the plasma [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>PCSK9 inhibition has the potential to provide a complementary mechanism to other LLTs to significantly reduce LDL-C beyond the efficacy of statins [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. Alirocumab (formerly REGN727/SAR236553; Sanofi-Regeneron) is a fully human, monoclonal antibody targeted to PCSK9 currently in Phase 3 development for the treatment of hypercholesterolemia.</p><p>In Phase 2 trials, alirocumab demonstrated significant reductions in LDL-C levels in patients receiving concomitant statin or statin plus ezetimibe therapy [NCT01288443; NCT01266876; NCT01288469; 21, 23, 24]. In these studies, alirocumab significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) reduced mean LDL-C levels by up to 72.4&#x000a0;%, and also showed favorable trends in other atherogenic lipid parameters including lipoprotein(a) [Lp(a)], triglycerides, non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein (Apo) B, and anti-atherogenic fractions HDL-C and Apo A1. Specifically, a Phase 2 trial demonstrated that alirocumab reduced mean LDL-C levels by up to 67.9&#x000a0;% (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) in patients with heFH [<xref ref-type="bibr" rid="CR24">24</xref>]. No dose-limiting adverse events (AEs) were identified in the Phase 2 studies [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], with the most common treatment-emergent AE (TEAE) in patients receiving alirocumab being mild injection site reaction. Five serious AEs (SAEs) occurred in four patients (1.5&#x000a0;%) who received alirocumab and two SAEs occurred in two patients (2.6&#x000a0;%) who received placebo.</p><p>The ODYSSEY Phase 3 alirocumab clinical trial program is designed to further assess the efficacy and safety of alirocumab in a range of clinical settings. The trials within the program evaluate a treat-to-goal approach, using a flexible dosing strategy for individualized therapy based on degree of LDL-C lowering required to achieve an adequate treatment response. This approach is designed to address patient populations unable to achieve desired LDL-C levels with the current standard of care. The program comprises a total of 14 studies planned to include more than 23,500 patients in over 2,000 study centers worldwide. Of these studies, the ODYSSEY program also includes a large cardiovascular outcomes trial evaluating the long-term impact of alirocumab and lower levels of LDL-C on the occurrence of cardiovascular events in 18,000 patients after a recent (&#x0003c;52&#x000a0;weeks) acute coronary syndrome event, with a randomized treatment period of 64&#x000a0;months. The aim of the ODYSSEY FH studies is to assess the efficacy and safety of alirocumab in patients with heFH who, despite their maximally-tolerated statin dose, with or without other LLT, continue to have suboptimal LDL-C levels and require additional pharmacologic management.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study Design</title><p>All three Phase 3 ODYSSEY FH clinical trials are multicenter, multinational, randomized, double-blind, placebo-controlled studies designed to evaluate the efficacy and safety of alirocumab in patients with heFH not adequately controlled with their current LLT.</p><p>The FH I study (ClinicalTrials.gov identifier: NCT01623115) is being conducted at 89 sites across North America, Europe and South Africa, and has a planned population of 471 patients. The FH II study (ClinicalTrials.gov identifier: NCT01709500) is being conducted at 26 sites across Europe and has a planned population of 250 patients.</p><p>Both the FH I and II studies enroll heFH patients who have LDL-C levels &#x02265;70&#x000a0;mg/dL at the screening visit and have a history of documented CVD, or heFH patients with LDL-C &#x02265;100&#x000a0;mg/dL at the screening visit without a history of documented CVD (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).</p><p>The HIGH FH study (ClinicalTrials.gov identifier: NCT01617655) is being conducted at 33 sites across North America, Europe and South Africa, and has a planned population of 105 patients with heFH and LDL-C levels &#x02265;160&#x000a0;mg/dL at the screening visit (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Study designs. <bold>a</bold> ODYSSEY FH I, <bold>b</bold> ODYSSEY FH II and <bold>c</bold> ODYSSEY HIGH FH. <italic>CV</italic> cardiovascular, <italic>heFH</italic> heterozygous familial hypercholesterolemia, <italic>LDL-C</italic> low-density lipoprotein cholesterol, <italic>LLT</italic> lipid-lowering therapy, <italic>NCEP ATP III TLC</italic> National Cholesterol Education Program Adult Treatment Panel III Therapeutic Lifestyle Changes, <italic>Q2W</italic> every 2&#x000a0;weeks, <italic>R</italic> randomization, <italic>SC</italic> subcutaneous. <sup>a</sup>At the end of the double-blind treatment period, patients will be offered the possibility to enter an open-label extension study, in which they will receive alirocumab. If patients opt out of entering the open-label treatment period, they will enter the 8-week follow-up period</p></caption><graphic xlink:href="10557_2014_6523_Fig1_HTML" id="MO1"/></fig></p><p>The studies are being performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and all applicable amendments laid down by the World Medical Assemblies and the International Conference Harmonisation guidelines for Good Clinical Practice. Institutional review board or independent ethics committee approval of the protocols and informed consent forms were obtained from each study site, and written informed consent was obtained from all patients.</p></sec><sec id="Sec4"><title>Study Objectives</title><p>The primary efficacy objective in all three studies is to demonstrate the reduction of LDL-C by alirocumab, in comparison with placebo, as add-on therapy to stable, maximally tolerated daily statin therapy, with or without other LLT, after 24&#x000a0;weeks of treatment in patients with heFH. Secondary objectives common to all three studies include the evaluation of the effect of alirocumab in comparison with placebo on LDL-C after 12&#x000a0;weeks of treatment; the effect of alirocumab on other lipid parameters, e.g., Apo B, non-HDL-C, total cholesterol, Lp(a), HDL-C, triglycerides and Apo A1 levels; the long-term effect of alirocumab on LDL-C; the safety and tolerability of alirocumab; and evaluation of the development of anti-alirocumab antibodies.</p></sec><sec id="Sec5"><title>Inclusion Criteria</title><p>The principal inclusion criteria for all three studies are patients with heFH who are not adequately controlled with a maximally tolerated stable daily dose of statin for at least 4&#x000a0;weeks prior to the screening visit, with or without other LLT (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Principal inclusion and exclusion criteria for ODYSSEY FH I, FH II, and HIGH FH</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="2">Principal inclusion criteria for all three studies</td></tr><tr><td colspan="2">&#x02003;Patients with heFH who are not adequately controlled<sup>a</sup> with a maximally-tolerated stable daily dose of statin<sup>b</sup> for at least 4&#x000a0;weeks prior to the screening visit, with or without other LLT</td></tr><tr><td colspan="2">Principal exclusion criteria</td></tr><tr><td colspan="2">&#x02003;Not on a stable dose of LLT (including statin) for at least 4&#x000a0;weeks and/or fenofibrate for at least 6&#x000a0;weeks, as applicable, prior to the screening visit or from screening to randomization</td></tr><tr><td colspan="2">&#x02003;Currently taking a statin that is not simvastatin, atorvastatin or rosuvastatin taken daily at a registered dose</td></tr><tr><td colspan="2">&#x02003;Receiving daily doses above atorvastatin 80&#x000a0;mg, rosuvastatin 40&#x000a0;mg or simvastatin 40&#x000a0;mg (except for patients on simvastatin 80&#x000a0;mg for more than 1&#x000a0;year, who are eligible)</td></tr><tr><td colspan="2">&#x02003;Use of fibrates, other than fenofibrate, within 6&#x000a0;weeks of the screening visit</td></tr><tr><td colspan="2">&#x02003;Fasting serum triglycerides &#x0003e;400&#x000a0;mg/dL (&#x0003e;4.52&#x000a0;mmol/L) at the screening visit</td></tr><tr><td colspan="2">&#x02003;Known history of homozygous FH</td></tr><tr><td>FH I and II</td><td>HIGH FH</td></tr><tr><td>History of documented CVD and LDL-C &#x0003c;70&#x000a0;mg/dL (&#x0003c;1.81&#x000a0;mmol/L) at the screening visit<break/>Without history of documented CVD and LDL-C &#x0003c;100&#x000a0;mg/dL (&#x0003c;2.59&#x000a0;mmol/L) at the screening visit</td><td>LDL-C &#x0003c;160&#x000a0;mg/dL (&#x0003c;4.14&#x000a0;mmol/L) at the screening visit AND patient only on statin monotherapy without additional LLT</td></tr></tbody></table><table-wrap-foot><p>
<italic>CVD</italic> cardiovascular disease, <italic>FH</italic> familial hypercholesterolemia, <italic>heFH</italic> heterozygous familial hypercholesterolemia, <italic>LDL-C</italic> low-density lipoprotein cholesterol, <italic>LLT</italic> lipid-lowering therapy, <italic>MI</italic> myocardial infarction</p><p>
<sup>a</sup>FH I and II: not adequately controlled defined as an LDL-C &#x02265;70&#x000a0;mg/dL at the screening visit in patients with a history of documented CVD OR LDL-C &#x02265;100&#x000a0;mg/dL at the screening visit in patients without a history of documented CVD. HIGH FH: not adequately controlled defined as an LDL-C &#x02265;160&#x000a0;mg/dL at the screening visit</p><p>
<sup>b</sup>Maximally-tolerated statin dose defined as: the highest tolerable registered dose of daily statin currently administered to the patient, that is rosuvastatin 20&#x000a0;mg or 40&#x000a0;mg daily; atorvastatin 40&#x000a0;mg or 80&#x000a0;mg daily; simvastatin 80&#x000a0;mg daily (if already on this dose for &#x0003e;1&#x000a0;year). Patients who are not able to be on any of the above statin doses should be treated with the dose of daily atorvastatin, rosuvastatin, or simvastatin which is considered appropriate for the patient, according to the investigator&#x02019;s judgment</p></table-wrap-foot></table-wrap></p><p>The diagnosis of heFH must be made either by genotyping or clinical criteria. For those patients not genotyped, the clinical diagnosis may be based on either the Simon Broome criteria [<xref ref-type="bibr" rid="CR26">26</xref>], meeting the criteria for definite FH, or the World Health Organization (WHO)/Dutch Lipid Network criteria [<xref ref-type="bibr" rid="CR27">27</xref>] with a score of &#x0003e;8 points.</p></sec><sec id="Sec6"><title>Exclusion Criteria</title><p>The principal exclusion criteria for the FH I and II studies include patients with different LDL-C thresholds depending on their cardiovascular risk status: LDL-C &#x0003c;70&#x000a0;mg/dL (&#x0003c;1.81&#x000a0;mmol/L) in patients with history of documented CVD and LDL-C &#x0003c;100&#x000a0;mg/dL (&#x0003c;2.59&#x000a0;mmol/L) in patients without history of documented CVD.</p><p>The principal exclusion criterion for the HIGH FH study includes patients with an LDL-C level of &#x0003c;160&#x000a0;mg/dL (&#x0003c;4.14&#x000a0;mmol/L) at the screening visit (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Other key exclusion criteria common to the three studies are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p></sec><sec id="Sec7"><title>Study Procedures</title><p>The three FH studies consist of three periods: a screening period of up to 3&#x000a0;weeks, during which the patient or another designated person is trained to self-inject/inject study medication (1&#x000a0;mL administered via auto-injector); a 78-week double-blind treatment period; and an 8-week off-treatment follow-up period. It should be noted that, at the end of the 78-week treatment period in each study, patients will be offered the possibility to enter an open-label extension study, in which they will receive alirocumab. If patients opt out of entering the open-label treatment period, they will enter the 8-week follow-up period.</p><p>In FH I, FH II and HIGH FH, all eligible patients are randomized 2:1 to alirocumab or placebo. Randomization is stratified according to history of myocardial infarction (MI) or ischemic stroke for balance across study arms, intensity of statin treatment (atorvastatin 40 to 80&#x000a0;mg daily, or rosuvastatin 20 to 40&#x000a0;mg daily versus simvastatin irrespective of the daily dose, atorvastatin below 40&#x000a0;mg daily or rosuvastatin below 20&#x000a0;mg daily), and geographic region (where applicable).</p><p>At randomization, treatment kit numbers are allocated using a centralized treatment allocation system, which is either an interactive voice response system or an interactive web response system, depending on the site preference. Study patients, principal investigators and study site personnel remain blinded to all randomization assignments throughout the study. All lipid and anti-drug antibody results collected after randomization are masked.</p><p>In the three studies, the first auto-injection during the double-blind treatment period takes place at the site on the day of randomization (Week 0). Subsequent auto-injections are done by the patient or another designated person such as a spouse or relative at a patient-preferred location and occur every 2&#x000a0;weeks.</p><p>In FH I and FH II, patients randomized to alirocumab will receive a 75&#x000a0;mg 1&#x000a0;mL dose every 2&#x000a0;weeks (Q2W). Patients randomized to placebo will receive a 1&#x000a0;mL subcutaneous placebo injection in an identical auto-injector to maintain blinding. At Week 12, patients randomized to alirocumab undergo a dose uptitration to 150&#x000a0;mg Q2W, also given as a 1&#x000a0;mL auto-injection, if the Week 8 LDL&#x000ad;C level is &#x02265;70&#x000a0;mg/dL (1.81&#x000a0;mmol/L). The continuation of the 75&#x000a0;mg dose or dose up-titration to the 150&#x000a0;mg dose will occur in an automated process without site or patient awareness.</p><p>In HIGH FH, at study entry, patients have an LDL-C level of &#x02265;160&#x000a0;mg/dL (4.14&#x000a0;mmol/L) and they will be randomized to receive a 150-mg 1&#x000a0;mL dose of alirocumab or placebo-alirocumab, without the uptitration process, from randomization to the end of the 78-week double-blind treatment period.</p><p>During the three FH studies, all patients are asked to follow a stable, National Cholesterol Education Program Adult Treatment Panel III Therapeutic Lifestyle Changes diet or equivalent throughout the entire study duration from screening to completion.</p></sec><sec id="Sec8"><title>Key Study Endpoints and Assessments</title><p>The primary efficacy endpoint in all three studies is the percent change in calculated LDL-C from baseline to Week 24, using all LDL-C values regardless of adherence to treatment (intent-to-treat [ITT] approach). Key secondary endpoints are summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Primary and key secondary endpoints common to FH I, FH II and HIGH FH</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Primary endpoint</td></tr><tr><td>&#x02003;% change in calculated LDL-C from baseline to Week 24 in the ITT population, using all LDL-C values regardless of adherence to treatment (ITT estimand)</td></tr><tr><td>Key secondary endpoints</td></tr><tr><td>&#x02003;% change in calculated LDL-C from baseline to Week 24 in the mITT population, using all LDL-C values during the efficacy treatment period (on-treatment estimand)</td></tr><tr><td>&#x02003;% change in LDL-C from baseline to Week 12 (ITT estimand)</td></tr><tr><td>&#x02003;% change in LDL-C from baseline to Week 12 (on-treatment estimand)</td></tr><tr><td>&#x02003;% change in Apo B from baseline to Week 24 (ITT estimand)</td></tr><tr><td>&#x02003;% change in Apo B from baseline to Week 24 (on-treatment estimand)</td></tr><tr><td>&#x02003;% change in non-HDL-C from baseline to Week 24 (ITT estimand)</td></tr><tr><td>&#x02003;% change in non-HDL-C from baseline to Week 24 (on-treatment estimand)</td></tr><tr><td>&#x02003;% change in total cholesterol from baseline to Week 24 (ITT estimand)</td></tr><tr><td>&#x02003;% change in Apo B from baseline to Week 12 (ITT estimand)</td></tr><tr><td>&#x02003;% change in non-HDL-C from baseline to Week 12 (ITT estimand)</td></tr><tr><td>&#x02003;% change in total cholesterol from baseline to Week 12 (ITT estimand)</td></tr><tr><td>&#x02003;% change in calculated LDL-C from baseline to Week 52 (ITT estimand)</td></tr><tr><td>&#x02003;Proportion of very high CV risk patients reaching calculated LDL-C &#x0003c;70&#x000a0;mg/dL (1.81&#x000a0;mmol/L) or high CV risk patients reaching calculated LDL-C &#x0003c;100&#x000a0;mg/dL (2.59&#x000a0;mmol/L) at Week 24 (ITT estimand)</td></tr><tr><td>&#x02003;Proportion of very high CV risk patients reaching calculated LDL-C&#x02009;&#x0003c;&#x02009;70&#x000a0;mg/dL (1.81&#x000a0;mmol/L) or high CV risk patients reaching calculated LDL-C &#x0003c;100&#x000a0;mg/dL (2.59&#x000a0;mmol/L) at Week 24 (on-treatment estimand)</td></tr><tr><td>&#x02003;Proportion of patients reaching LDL-C &#x0003c;70&#x000a0;mg/dl (1.81&#x000a0;mmol/L) at Week 24 (ITT estimand)<sup>a</sup>
</td></tr><tr><td>&#x02003;Proportion of patients reaching LDL-C &#x0003c;70&#x000a0;mg/dl (1.81&#x000a0;mmol/L) at Week 24 (on-treatment estimand)<sup>a</sup>
</td></tr><tr><td>&#x02003;% change in Lp(a) from baseline to Week 24 (ITT estimand)</td></tr><tr><td>&#x02003;% change in HDL-C from baseline to Week 24 (ITT estimand)</td></tr><tr><td>&#x02003;% change in fasting TG from baseline to Week 24 (ITT estimand)</td></tr><tr><td>&#x02003;% change in Apo A1 from baseline to Week 24 (ITT estimand)</td></tr><tr><td>&#x02003;% change in Lp(a) from baseline to Week 12 (ITT estimand)</td></tr><tr><td>&#x02003;% change in HDL-C from baseline to Week 12 (ITT estimand)</td></tr><tr><td>&#x02003;% change in fasting TG from baseline to Week 12 (ITT estimand)</td></tr><tr><td>&#x02003;% change in Apo A1 from baseline to Week 12 (ITT estimand)</td></tr></tbody></table><table-wrap-foot><p>
<italic>Apo</italic> apolipoprotein, <italic>FH</italic> familial hypercholesterolemia, <italic>HDL-C</italic> high-density lipoprotein cholesterol, <italic>ITT</italic> intent-to-treat, <italic>LDL-C</italic> low-density lipoprotein cholesterol, <italic>Lp(a)</italic> lipoprotein(a), <italic>mITT</italic> modified ITT, <italic>TG</italic> triglycerides</p><p>
<sup>a</sup>Proportion of patients reaching LDL-C &#x0003c;70&#x000a0;mg/dL (ITT and on-treatment estimand) are the last key secondary endpoints for HIGH FH</p></table-wrap-foot></table-wrap></p><p>In FH I, II and HIGH FH, LDL-C will be calculated using the Friedewald formula at screening and at all time points during the double-blind treatment periods. In FH I and II, if triglycerides exceed 400&#x000a0;mg/dL (4.52&#x000a0;mmol/L) then the central laboratory will reflexively measure LDL-C (via the beta quantification method) rather than calculating it. LDL-C will also be measured (via the beta quantification method) at Week 0 and Week 24.</p><p>On-site patient assessments take place at Weeks 0, 12, 24, 36, 52, 64, 78, and 86, the end-of-study visit. All laboratory tests are performed by the central laboratory.</p><p>Safety parameters (AEs [including adjudicated CV events categorized as CHD death, non-fatal MI, fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization, congestive heart failure requiring hospitalization], laboratory data [blood biochemistry, hematology and urinalysis], vital signs and electrocardiogram) are assessed throughout the study.</p></sec><sec id="Sec9"><title>Statistical Design and Analysis</title><sec id="Sec10"><title>Sample Size Determination</title><p>In each study (FH I, FH II and HIGH FH), a total sample size of 45 patients (30 in the alirocumab and 15 in the placebo group) will have 95&#x000a0;% power to detect a difference in mean percent change in LDL-C of 30&#x000a0;% with a 0.05 two-sided significance level, assuming a common standard deviation of 25&#x000a0;% and all these 45 patients having an evaluable primary endpoint.</p><p>However, to meet regulatory requirements across the program, sample sizes were increased to assess the safety of alirocumab appropriately. Therefore, the final total sample sizes were increased and rounded to 471 in FH I, 250 in FH II and 105 in HIGH FH.</p></sec><sec id="Sec11"><title>Analysis Populations for Each of the FH Studies</title><sec id="d30e786"><title>Primary Analysis</title><p>The primary analysis population will be the ITT population and will comprise all randomized patients with at least one baseline calculated LDL-C value available and at least one calculated LDL-C value available between Weeks 4 and 24 (regardless of treatment adherence). The percent change from baseline in LDL-C at Week 24 will be analyzed using a mixed effect model with repeated measures (MMRM) approach. All available post-baseline data from Week 4 to 24 (on- and off-treatment) will be used, in which missing data will be accounted for by the MMRM [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. The model includes fixed categorical effects of treatment group, randomization strata time point, treatment-by-time point and strata-by-time point interaction as well as the continuous fixed covariates of baseline LDL-C value and baseline value-by-time point interaction.</p></sec><sec id="d30e797"><title>Secondary Analysis</title><p>A hierarchical procedure will be used to control type I error and handle multiple secondary endpoints analyses. If the primary endpoint analysis (ITT) is significant at 5&#x000a0;% alpha level, key secondary efficacy endpoints will be tested sequentially in the order given in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. In particular, LDL-C reduction at Week 24 will be analyzed on-treatment in the modified ITT population (i.e. patients with at least one baseline and at least one calculated LDL-C value available on-treatment between Week 4 and 24) if the primary analysis is significant in the ITT population.</p><p>Continuous secondary endpoints, except Lp(a) and triglycerides, will be analyzed using the same MMRM model as for the primary endpoint. Lp(a) and triglycerides (which have a non-Gaussian distribution), and the binary secondary endpoints (proportion of patients with LDL-C &#x0003c;70&#x000a0;mg/dL and &#x0003c;100&#x000a0;mg/dL) will be analyzed using a multiple imputation approach for handling of missing values followed by robust regression [<xref ref-type="bibr" rid="CR30">30</xref>] (for Lp(a) and triglycerides) or logistic regression (for binary endpoints).</p></sec></sec><sec id="Sec12"><title>Safety Analysis</title><p>AEs (including adjudicated CV events), laboratory parameters, and vital signs will be reported descriptively, based on the safety population (all randomized patients who received at least one dose or partial dose of study treatment). The safety analysis will focus on the TEAE period defined as the time from the first double-blind dose to the last double-blind dose of the investigational product +70&#x000a0;days (10&#x000a0;weeks).</p><p>Patients entering the open-label extension study will be followed up to their last visit in the double-blind treatment period and their TEAE period will be truncated at this visit.</p><sec id="d30e817"><title>Timing of Analysis</title><p>The analysis will be conducted in two steps. The first step will be the main efficacy and safety analyses conducted as soon as all patients have been randomized and have at least all their data up to Week 52 collected and validated. In this step, the final analysis of the primary and secondary efficacy endpoints up to Week 52 will be performed as well as the safety analysis on all safety data collected and validated at the time of the first analysis.</p><p>Of note, the results of the first analysis will not be used to change the conduct of the ongoing study in any aspect. Since the analyses of primary and key secondary efficacy endpoints will be final at the time of first step analysis, the significance level for the study remains at 0.05. The second step in the analysis will be conducted at the end of the study and will consist of the final analysis of Week 78 efficacy endpoints and the final safety analysis.</p></sec></sec></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p>A recent consensus statement has been issued urging a worldwide need to address the underdiagnosis and undertreatment of patients with heFH [<xref ref-type="bibr" rid="CR4">4</xref>]. The prevalence of heFH comes from estimates based on a theoretical frequency of 1/500 in the general population, and recent numbers indicate that approximately 689,900 individuals in the USA and Canada, 527,500 in Europe and 100,000 in South Africa have heFH [<xref ref-type="bibr" rid="CR4">4</xref>]. Furthermore, some studies have indicated the prevalence can range from 1/500 to 1/200, and based on extrapolations, it is estimated that there are between 14 and 34 million individuals with heFH worldwide [<xref ref-type="bibr" rid="CR4">4</xref>]. In many countries, however, less than 1&#x000a0;% of patients are diagnosed [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>A diagnosis of heFH is typically made based on family history, clinical history of CHD, physical examination for xanthomas and corneal arcus, and very high levels of LDL-C; it can also be made by genotyping [<xref ref-type="bibr" rid="CR31">31</xref>]. However, despite the increased understanding of genetic causes and direct detection of mutations in the LDLR, APOB, PCSK9 and LDLRAP genes, the vast majority of diagnoses still rely on the more historical clinical criteria.</p><p>Although it has been demonstrated that statin therapy, with or without other LLT, can reduce the risk of CHD in patients with heFH [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>], many patients with heFH still do not achieve desired LDL-C levels [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] and more intensive treatment options for these high-risk patients are required [<xref ref-type="bibr" rid="CR4">4</xref>]. To help address this unmet need, new approaches to lowering LDL-C, including monoclonal antibodies to PCSK9 administered as subcutaneous injection, are currently in development.</p><p>In evaluating the efficacy and safety of such antibodies to PCSK9, a Phase 2, randomized controlled trial of alirocumab conducted in patients with heFH and LDL-C levels &#x0003e;100&#x000a0;mg/dL despite their current LLT of a statin, with or without ezetimibe, showed that alirocumab was well tolerated and also showed statistically significant reductions in LDL-C levels at all doses of alirocumab compared with placebo [<xref ref-type="bibr" rid="CR24">24</xref>]. With the large reductions in LDL-C, up to 94&#x000a0;% of patients achieved LDL-C levels &#x0003c;100&#x000a0;mg/dL and up to 81&#x000a0;% achieved levels &#x0003c;70&#x000a0;mg/dL [<xref ref-type="bibr" rid="CR24">24</xref>]. In another Phase 2, randomized controlled trial with evolocumab in heFH patients with LDL-C levels &#x0003e;100&#x000a0;mg/dL despite receiving statin therapy, with or without ezetimibe, findings showed substantial reductions in LDL-C levels with evolocumab compared with placebo [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>The ODYSSEY FH studies are Phase 3 studies aiming to further demonstrate the potential of alirocumab as an effective therapeutic option for patients with this severe disorder. The uptitration dosing strategy in FH I and FH II allows for flexibility and individualized therapy based on the degree of LDL-C reduction required to achieve the desired treatment response. In HIGH FH, where patients entered the study with LDL-C values &#x02265;160&#x000a0;mg/dL despite receiving a maximally tolerated statin dose, with or without ezetimibe, it was deemed appropriate to initiate the higher, 150&#x000a0;mg Q2W, dose of alirocumab. In addition, the option for patients to enter an open-label extension study at the end of the double-blind treatment period will allow for further assessment of the efficacy and safety of alirocumab.</p></sec></body><back><ack><p>The ODYSSEY FH studies were supported by Sanofi and Regeneron Pharmaceuticals, Inc. The design and conduct of the study, as well as analysis of the study data and opinions, conclusions, and interpretation of the data, are the responsibility of the authors. Medical writing support in the preparation of this publication was provided by Betty Thompson, Ph.D., of Prime Medica and sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The authors were responsible for all content and editorial decisions and received no honoraria related to the development/presentation of this publication.</p><sec id="d30e896"><title>Investigators</title><p><bold>FH I</bold></p><p><bold>Canada:</bold> Robert DuFour (Montreal, Quebec); Jean Bergeron (Sainte-Foy, Quebec); Daniel Gaudet (Montreal, Quebec); Patrice Perron (Sherbrooke, Quebec); Lawrence Leiter (Toronto, Ontario)</p><p><bold>United States:</bold> Thomas Barringer (Charlotte, NC); Robert Fishberg (Summit, NJ); Henry Ginsberg (New York, NY); Anne Goldberg (St Louis, MO); John Guyton (Durham, NC); Linda Hemphill (Boston, MA); John Homan (Newport Beach, CA); Patrick Moriarty (Kansas City, KS); Galal Salem (Bell Gardens, CA); Erich Schramm (Ponte Vedra, FL); Prediman Shah (Los Angeles, CA); Chad Wadell (Mission Viejo, CA); Ralph Wade (Bountiful, UT); Jonathan Purnell (Portland, OR); Robert Weiss (Lewiston, ME); Marina Cuchel (Philadelphia, PA); Emanuel Shaoulian (Newport Beach, CA); Robert Greenfield (Fountain Valley, CA); Traci Turner (Cincinnati, OH); Alan Brown (Oakbrook Terrace, IL); Jeffrey Geohas (Evanston, IL); Frederick Dunn (Dallas, TX)</p><p><bold>Austria:</bold> Rudolf Prager (Wien); Hermann Toplak (Graz); Evelyn Fliesser-Goerzer (St Stefan)</p><p><bold>Czech Republic:</bold> Marketa Galovcova (Praha 4); Josef Machacek (Zlin); Jan Zeman (Praha 8); Stanislav Zemek (Uhersk&#x000e9; Hradi&#x00161;t&#x0011b;)</p><p><bold>Denmark:</bold> Erik Schmidt (Aalborg); Kristian Thomsen (Esbjerg); Pernille Correll (Roskilde)</p><p><bold>France:</bold> Eric Bruckert (Paris); Michel Krempf (Saint-Herblain); Michel Farnier (Dijon); Gerald Luc (Lille)</p><p><bold>Israel:</bold> Hofit Cohen (Tel-Hashomer); Dov Gavish (Holon); Osamah Hussein (Safed); Daniel Schurr (Jerusalem)</p><p><bold>Netherlands:</bold> S.H.J. Donders (Groningen); G. Kees Hovingh (Amsterdam); P. Viergever (Den Helder); H.H. Vincent (Nieuwegein); A. Loualidi (Delfzijl); S.C.C. Hartong (Sliedrecht); A.A. Kroon (Maastricht); Jacqueline De Graaf (Nijmegen)</p><p><bold>Norway:</bold> Anders Hovland (Bodo)</p><p><bold>Russia:</bold> Evgenia Akatova (Moscow); Vadim Arkhipovsky (Arkhangelsk); Elena Demchenko (St. Petersburg); Victor Gurevich (St. Petersburg); Gadel Kamalov (Kazan); Anastasia Lebedeva (Moscow); Viacheslav Marasaev (Yaroslavl); Svetlana Mustafina (Novosibirsk); Andrey Susekov (Moscow)</p><p><bold>Spain:</bold> Luis Alvarez-Sala (Madrid); Fernando Civeira (Zaragoza-Aragon); Jose Luis Diaz Diaz (La Coruna- Galicia); Nuria Plana Gil (Reus-Tarragona); Rodrigo Alonso (Madrid); Francisco Fuentes Jimenez (Cordoba); Xavier Pinto Sala (Barcelona); Emilio Ros (Barcelona); Jose Luis Mostaza Prieto (Madrid)</p><p><bold>Sweden:</bold> A. Ohlsson-&#x000d6;nerud (Stockholm); Stefano Romeo (Goteborg)</p><p><bold>United Kingdom:</bold> Graham Bayly (Bristol); Jacob George (Dundee); Basil Issa (Manchester); Gordon Ferns (Brighton)</p><p><bold>South Africa:</bold> F.C.J. Bester (Bloemfontein); Dirk Blom (Cape Town); Lesley Burgess (Cape Town); Shaunagh Emanuel (Cape Town); Nyda Fourie (Bloemfontein); Maria Pretorius (Cape Town); Frederick Raal (Johannesburg); Prashilla Soma (Pretoria); Shirley Middlemost (Western Cape)</p><p><bold>FH II</bold></p><p><bold>Czech Republic</bold>: Richard Ceska (Praha 2); Vladmir Blaha (Hradec Kralove); Jana Cepova (Praha 5); Hana Halamkova (Vyskov); Lucie Solcova (Trutnov); Jana Jirouskova (Praha 8).</p><p><bold>Netherlands:</bold> G. Kees Hovingh (Amsterdam); Stan Peter Janssen (Utrecht); H.W.O. Roeters van Lennep (Goes); Roel P.T. Troquay (Venlo); B.E. Groenemeijer (Apeldoorn); J.W. Hans Louwerenburg (Enschede); Marcel A. van de Ree (Utrecht); Adriaan Kooy (Hoogeveen); Suat Simsek (Alkmaar); Ben P.M. Imholz (Waalwijk); P.W. Kamphuisen (Groningen); Castro Cabezas (Rotterdam); Dick Basart (Hoorn).</p><p><bold>Norway:</bold> Gisle Langslet (Oslo); Eli Heggen (Oslo).</p><p><bold>UK</bold>: See Kwok (Manchester); D.D.R. Nair (London); Alan Rees (Cardiff); R.D.G. Neely (Newcastle upon Tyne); Elizabeth Hughes (West Bromwich).</p><p><bold>HIGH FH</bold></p><p><bold>Canada:</bold> Patrice Perron (Sherbrooke, Quebec); Jean Bergeron (Sainte-Foy, Quebec)</p><p><bold>United States:</bold> Henry Ginsberg (New York, NY); John Guyton (Durham, NC); John Homan (Newport Beach, CA); Marina Cuchel (Philadelphia, PA); Rashmi Schramm (Ponte Vedra, FL); Robert Greenfield (Fountain Valley, CA); Traci Turner (Cincinnati, OH); Lisa Martin (Washington, DC); Frederick Dunn (Dallas, TX); Robert DeLuca (Miami, FL); Galal Salem (Bell Gardens, CA)</p><p><bold>Netherlands:</bold> E.S.G. Stroes (Amsterdam); S.H.J. Donders (Groningen); Marcel A. van de Ree (Utrecht); J.P.R. Herrman (Amsterdam); M.V. Huisman (Leiden)</p><p><bold>Russia:</bold> Elena Demchenko (St. Petersburg); Anastasia Lebedeva (Moscow); Gadel Kamalov (Kazan); Vadim Arkhipovsky (Arkhangelsk); Viacheslav Marasaev (Yaroslavl); Evgenia Akatova (Moscow); Victor Gurevich (St. Petersburg); Andrey Susekov (Moscow)</p><p><bold>South Africa:</bold> F.C.J. Bester (Bloemfontein); Frederick Raal (Johannesburg); Shirley Middlemost (Western Cape); Nyda Fourie (Bloemfontein); Maria Pretorius (Cape Town)</p></sec><sec id="d30e1002"><title>Steering Committee</title><p>Chairman: Henry Ginsberg, MD (Irving Institute for Clinical and Translational Research, Columbia University New York, NY USA). Members: Jennifer G. Robinson, MD, MPH (The University of Iowa, Iowa City, IA USA); Daniel J. Rader, MD (Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine Philadelphia, PA USA); Christopher P. Cannon, MD (Senior Investigator, TIMI Study Group; Professor of Medicine, Harvard Medical School Cardiovascular Division, Brigham and Women&#x02019;s Hospital, Boston, MA USA); Helen Colhoun, MD, MFPHM (Clinical Centre, University of Dundee, Ninewells Hospital &#x00026; Medical School, Dundee, UK); John J.P. Kastelein, MD (Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands); Michel Farnier, MD (Point M&#x000e9;dical, D&#x000e9;partement d&#x02019;Endocrinologie et de Lipidologie, Dijon, France).</p></sec><sec id="d30e1007"><title>Data Monitoring Committee</title><p>DMC Chairman: Anders Olsson, MD (Bromma, Sweden). Members: David Waters, MD (Division of Cardiology, San Francisco General Hospital, San Francisco, CA USA); Dominique Larrey, MD (H&#x000f4;pital Saint-Eloi Service d&#x02019;h&#x000e9;pato-gastro-ent&#x000e9;rologie, Montpellier, France); Robert S Rosenson, MD (Director, Cardiometabolic Disorders, Mount Sinai Heart; Professor of Medicine, Mount Sinai School of Medicine, New York, NY USA); Peter A. Patriarca, MD (Biologics Consulting Group, Inc., Alexandria, VA USA); Geert Molenberghs, Biostatistician (Center for Statistics (CenStat) Universiteit Hasselt Agoralaan 1, Diepenbeek, Belgium).</p></sec><sec id="d30e1012"><title>Clinical Events Committee (Reviewers), Duke Clinical Research Institute, Durham, NC USA</title><p>Pierluigi Tricoci, CEC Principal Investigator, Cardiology; Kenneth W Mahaffey, CEC Director, Cardiology; Renato D Lopes, Cardiology; Bimal R Shah, Cardiology; Rajendra H Metha, Cardiology; Matthew T Roe, Cardiology; Zubin Eapen, Cardiology; Luciana Armaganijan, Cardiology; Adriana Bertolami, Cardiology; Sergio Leonardi, Cardiology; Bradley J. Kolls, Neurology; J. Dedrick Jordan, Neurology; Gr&#x000e9;gory Ducrocq, Cardiology; Etienne Puymirat, Cardiology; Robin Mathews, Cardiology.</p></sec><sec id="d30e1017"><title>Disclosures</title><p>Dr. Kastelein is a consultant to and receives honoraria from: Regeneron, Sanofi, Eli Lilly, Pfizer, Amgen, Isis, Genzyme, Aegerion and Esperion. He is a recipient of the Lifetime Achievement Award of the Dutch Heart Foundation (2010T082).</p><p>Dr. Robinson is employed by a University that has received research funds from Amarin, Amgen, AstraZeneca, Daiichi-Sankyo, Esperion, Genetech/Hoffman La Roche, Glaxo-Smith Kline, Merck, Regeneron/Sanofi, Zinfandel/Takeda and is a consultant for Amgen, Pfizer, Sanofi and Regeneron.</p><p>Dr. Farnier reports having received grants, consulting fees and/or honoraria and delivering lectures for Abbott, Amgen, Boehringer-Ingelheim, Genzyme, Kowa, Merck and Co, Novartis, Pfizer, Recordati, Roche, Sanofi-Aventis, and SMB.</p><p>Dr. Langslet has received advisory board fees from Sanofi-Aventis and Janssen Pharmaceuticals.</p><p>Dr. Krempf has received grants, consulting fees and/or honoraria and delivering lectures for Abbott, Amgen, Astra Zeneca, BMS, Merck and Co, Novartis, Pfizer, Roche, Sanofi-Aventis.</p><p>Christelle Lorenzato and Marie T. Baccara-Dinet are employees of Sanofi.</p><p>Daniel A. Gipe is an employee of Regeneron.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Hobbs</surname><given-names>HH</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><etal/></person-group><person-group person-group-type="editor"><name><surname>Scriver</surname><given-names>CR</given-names></name><name><surname>Sly</surname><given-names>WS</given-names></name><name><surname>Childs</surname><given-names>B</given-names></name><etal/></person-group><article-title>Familial hypercholesterolemia</article-title><source>The metabolic and molecular bases of inherited disease</source><year>2001</year><edition>8</edition><publisher-loc>New York</publisher-loc><publisher-name>McGraw-Hill</publisher-name><fpage>2863</fpage><lpage>913</lpage></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">NICE clinical guidelines 71. Identification and management of familial hypercholesterolemia. Issue date: August 2008. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/nicemedia/live/12048/41697/41697.pdf">http://www.nice.org.uk/nicemedia/live/12048/41697/41697.pdf</ext-link>. Accessed Mar 2013.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>NJ</given-names></name><name><surname>Levy</surname><given-names>RI</given-names></name><name><surname>Fredrickson</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia</article-title><source>Circulation</source><year>1974</year><volume>49</volume><fpage>476</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.49.3.476</pub-id><pub-id pub-id-type="pmid">4813182</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><collab>for the European Atherosclerosis Society Consensus Panel</collab><etal/></person-group><article-title>Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><fpage>3478</fpage><lpage>90a</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/eht273</pub-id><pub-id pub-id-type="pmid">23956253</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neil</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>J</given-names></name><name><surname>Betteridge</surname><given-names>J</given-names></name><etal/></person-group><article-title>Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study</article-title><source>Eur Heart J</source><year>2008</year><volume>29</volume><fpage>2625</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehn422</pub-id><pub-id pub-id-type="pmid">18840879</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harada-Shiba</surname><given-names>M</given-names></name><name><surname>Sugisawa</surname><given-names>T</given-names></name><name><surname>Makino</surname><given-names>H</given-names></name><etal/></person-group><article-title>Impact of statin treatment on the clinical fate of heterozygous familial hypercholesteremia</article-title><source>J Atheroscler Thromb</source><year>2010</year><volume>17</volume><fpage>667</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.5551/jat.4143</pub-id><pub-id pub-id-type="pmid">20534948</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Versmissen</surname><given-names>J</given-names></name><name><surname>Oosterveer</surname><given-names>DM</given-names></name><name><surname>Yazdanpanah</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy of statins in familial hypercholesterolaemia: a long term cohort study</article-title><source>BMJ</source><year>2008</year><volume>337</volume><fpage>a2423</fpage><pub-id pub-id-type="doi">10.1136/bmj.a2423</pub-id><pub-id pub-id-type="pmid">19001495</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huijgen</surname><given-names>R</given-names></name><name><surname>Kindt</surname><given-names>I</given-names></name><name><surname>Verhoeven</surname><given-names>S</given-names></name><etal/></person-group><article-title>Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e9220</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0009220</pub-id><pub-id pub-id-type="pmid">20169164</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gitt</surname><given-names>AK</given-names></name><name><surname>J&#x000fc;nger</surname><given-names>C</given-names></name><name><surname>Smolka</surname><given-names>W</given-names></name><name><surname>Bestehorn</surname><given-names>K</given-names></name></person-group><article-title>Prevalence and overlap of different lipidabnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany</article-title><source>Clin Res Cardiol</source><year>2010</year><volume>99</volume><fpage>723</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1007/s00392-010-0177-z</pub-id><pub-id pub-id-type="pmid">20521058</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>AC</given-names></name><name><surname>Hopkins</surname><given-names>PN</given-names></name><name><surname>Toth</surname><given-names>PP</given-names></name><etal/></person-group><article-title>Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia</article-title><source>J Clin Lipidol</source><year>2011</year><volume>5</volume><issue>3, Supplement 1</issue><fpage>S1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jacl.2011.04.003</pub-id><pub-id pub-id-type="pmid">21600525</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pijlman</surname><given-names>AH</given-names></name><name><surname>Huijgen</surname><given-names>R</given-names></name><name><surname>Verhagen</surname><given-names>SN</given-names></name><etal/></person-group><article-title>Evaluation of cholesterol lowering treatments of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands</article-title><source>Atherosclerosis</source><year>2010</year><volume>209</volume><fpage>189</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2009.09.014</pub-id><pub-id pub-id-type="pmid">19818960</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>EA</given-names></name><name><surname>Strutt</surname><given-names>K</given-names></name><name><surname>Southworth</surname><given-names>H</given-names></name><collab>HeFH study group</collab><etal/></person-group><article-title>Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia</article-title><source>Am J Cardiol</source><year>2003</year><volume>92</volume><fpage>1287</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2003.08.009</pub-id><pub-id pub-id-type="pmid">14636905</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Stone N, Robinson J, Lichtenstein A, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2013.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abifadel</surname><given-names>M</given-names></name><name><surname>Varret</surname><given-names>M</given-names></name><name><surname>Rabes</surname><given-names>J-P</given-names></name><etal/></person-group><article-title>Mutations in PCSK9 cause autosomal dominant hypercholesterolemia</article-title><source>Nat Genet</source><year>2003</year><volume>34</volume><fpage>154</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/ng1161</pub-id><pub-id pub-id-type="pmid">12730697</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagace</surname><given-names>TA</given-names></name><name><surname>Curtis</surname><given-names>DE</given-names></name><name><surname>Garuti</surname><given-names>R</given-names></name><etal/></person-group><article-title>Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>2995</fpage><lpage>3005</lpage><pub-id pub-id-type="doi">10.1172/JCI29383</pub-id><pub-id pub-id-type="pmid">17080197</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>KN</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name><name><surname>Breslow</surname><given-names>JL</given-names></name></person-group><article-title>Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>2069</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1073/pnas.0409736102</pub-id><pub-id pub-id-type="pmid">15677715</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayne</surname><given-names>J</given-names></name><name><surname>Dewpura</surname><given-names>T</given-names></name><name><surname>Raymond</surname><given-names>A</given-names></name><etal/></person-group><article-title>Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture</article-title><source>Clin Chem</source><year>2011</year><volume>57</volume><fpage>1415</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2011.165191</pub-id><pub-id pub-id-type="pmid">21813713</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welder</surname><given-names>G</given-names></name><name><surname>Zineh</surname><given-names>I</given-names></name><name><surname>Pacanowski</surname><given-names>MA</given-names></name><etal/></person-group><article-title>High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol</article-title><source>J Lipid Res</source><year>2010</year><volume>51</volume><fpage>2714</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1194/jlr.M008144</pub-id><pub-id pub-id-type="pmid">20525997</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giugliano</surname><given-names>RP</given-names></name><name><surname>Desai</surname><given-names>NR</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><etal/></person-group><article-title>Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>2007</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61770-X</pub-id><pub-id pub-id-type="pmid">23141813</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koren</surname><given-names>MJ</given-names></name><name><surname>Scott</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>1995</fpage><lpage>2006</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61771-1</pub-id><pub-id pub-id-type="pmid">23141812</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenney</surname><given-names>JM</given-names></name><name><surname>Koren</surname><given-names>MJ</given-names></name><name><surname>Kereiakes</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/RENGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>59</volume><fpage>2344</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2012.03.007</pub-id><pub-id pub-id-type="pmid">22463922</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raal</surname><given-names>F</given-names></name><name><surname>Scott</surname><given-names>R</given-names></name><name><surname>Somaratne</surname><given-names>R</given-names></name><etal/></person-group><article-title>Low-density lipoprotein cholesterol-lowering effects of AMG-145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction in LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial</article-title><source>Circulation</source><year>2012</year><volume>126</volume><fpage>2408</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.144055</pub-id><pub-id pub-id-type="pmid">23129602</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>EM</given-names></name><name><surname>McKenney</surname><given-names>JM</given-names></name><name><surname>Hanotin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>1891</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1201832</pub-id><pub-id pub-id-type="pmid">23113833</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>EA</given-names></name><name><surname>Gipe</surname><given-names>D</given-names></name><name><surname>Bergeron</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60771-5</pub-id><pub-id pub-id-type="pmid">22633824</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>D</given-names></name><name><surname>Olsson</surname><given-names>AG</given-names></name><name><surname>Scott</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients. The GAUSS randomized trial</article-title><source>JAMA</source><year>2012</year><volume>308</volume><fpage>1545</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.25790</pub-id><pub-id pub-id-type="pmid">23073951</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Scientific Steering Committee on behalf of the Simon Register Group</collab></person-group><article-title>Risk of fatal coronary heart disease in familial hypercholesterolaemia</article-title><source>BMJ</source><year>1991</year><volume>303</volume><fpage>893</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/bmj.303.6807.893</pub-id><pub-id pub-id-type="pmid">1933004</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="book"><source>Familial Hypercholesterolaemia (FH): report of a second WHO consultation</source><year>1999</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>O</given-names></name><name><surname>Hung</surname><given-names>HM</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>R</given-names></name></person-group><article-title>MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets</article-title><source>J Biopharm Stat</source><year>2009</year><volume>19</volume><fpage>227</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1080/10543400802609797</pub-id><pub-id pub-id-type="pmid">19212876</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="book"><source>The prevention and treatment of missing data in clinical trials. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education</source><year>2010</year><publisher-loc>Washington, DC</publisher-loc><publisher-name>The National Academies Press</publisher-name></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehrotra</surname><given-names>DV</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name></person-group><article-title>Analysis of longitudinal clinical trials with missing data using multiple imputation in conjunction with robust regression</article-title><source>Biometrics</source><year>2012</year><volume>68</volume><fpage>1250</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1541-0420.2012.01780.x</pub-id><pub-id pub-id-type="pmid">22994905</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Civeira</surname><given-names>F</given-names></name></person-group><article-title>Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia</article-title><source>Atherosclerosis</source><year>2004</year><volume>173</volume><fpage>55</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2003.11.010</pub-id><pub-id pub-id-type="pmid">15177124</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>E</given-names></name><name><surname>Stender</surname><given-names>S</given-names></name><name><surname>Mata</surname><given-names>P</given-names></name><collab>Ezetimibe Study Group</collab><etal/></person-group><article-title>Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin</article-title><source>Am Heart J</source><year>2004</year><volume>148</volume><fpage>447</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2004.03.052</pub-id><pub-id pub-id-type="pmid">15389231</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>EA</given-names></name><name><surname>Ose</surname><given-names>L</given-names></name><name><surname>Retterstol</surname><given-names>K</given-names></name><etal/></person-group><article-title>Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia</article-title><source>J Clin Lipidol</source><year>2007</year><volume>1</volume><fpage>280</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jacl.2007.07.003</pub-id><pub-id pub-id-type="pmid">21291692</pub-id></element-citation></ref></ref-list></back></article>